[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fondazione del Piemonte per l'Oncologia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":397},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,51,80,107,132,166,193,225,248,270,295,320,346,376],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100632520","galenos-2-immunonutrition-in-head-and-neck-lung-and-rectal-cancer-patients-100632520",false,"NCT07514754","Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients","Use of an Immunonutrition Galenic Formulation in Head and Neck, Lung and Rectal Cancer Patients During Antineoplastic Treatments: A Prospective Study","GALENOS 2","Inclusion Criteria:\n\n* Written informed consent to study procedures\n* Male or female, age greater than 18 years\n* Histological or cytological documentation of head and neck squamous cell carcinoma, locally advanced rectal cancer, or lung cancer candidate for immunotherapy, chemotherapy, and\u002For radiotherapy according to standard clinical practice\n* ECOG Performance Status score less than 2\n* Adequate kidney, liver, and bone marrow function\n* Ability to understand, sign informed consent, and comply with study procedures\n\nExclusion Criteria:\n\n* Incomplete recovery from surgery before starting antineoplastic treatment\n* Other progressing malignancy or malignancy requiring active treatment within the last 3 years, except localized basal cell carcinoma, localized squamous cell carcinoma of the skin, or cervical carcinoma in situ\n* Active infection requiring systemic antibiotic therapy\n* Serious or unstable medical conditions, psychiatric disorders, or substance abuse interfering with study compliance\n* Receipt of any live vaccine within 30 days before study treatment\n* Active cardiac pacing\u002Fpacing implants\u002Fneurostimulators\u002Fhearing system not compatible with bioimpedance analysis\n* Edema and\u002For ascites not compatible with body weight evaluation and bioimpedance analysis\n* Enteral or parenteral nutritional support at baseline","ALL","18 Years",{"count":20,"type":21},52,"ESTIMATED","INTERVENTIONAL",[24],"NA","GALENOS 2 is a single-arm, single-center, phase II interventional study designed to evaluate the effects of a galenic immunonutrition dietary supplement in patients with head and neck squamous cell carcinoma, locally advanced rectal cancer, or lung cancer undergoing standard antineoplastic treatment. The study aims to assess whether the formula may reduce treatment-related toxicity and improve treatment compliance, using patients from the GALENOS 1 observational study as the control group for comparison",[27,28,29],"Head and Neck Squamous Cell Carcinoma","Locally Advanced Rectal Cancer","Lung Cancer",[31,27,28,29,32,33,34,35,36,37],"Immunonutrition","Treatment Toxicity","Supportive Care","Body Composition","Nutritional Status","Cytokines","Quality of Life","RECRUITING","2026-03-31",{"date":41,"type":42},"2026-04-07","ACTUAL",{"date":44,"type":42},"2025-10-03",{"date":46,"type":21},"2027-12-30",{"name":48,"class":49},"Fondazione del Piemonte per l'Oncologia","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":59,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":50},"100631992","endoscopic-nipple-sparing-mastectomy-through-a-single-axillary-incision-in-breast-cancer-100631992","NCT07507890","Endoscopic Nipple-Sparing Mastectomy Through a Single Axillary Incision in Breast Cancer","MINI-B - Minimally Invasive Endoscopic Mastectomy Using a Single Axillary Incision in Breast Cancer Patients: a Prospective Cohort Study","Mini-B","Inclusion Criteria:\n\n* Female participants aged 18 years or older.\n* Diagnosis of early-stage invasive breast cancer or ductal carcinoma in situ, including multifocal or multicentric disease.\n* Candidate for nipple-sparing mastectomy with immediate direct-to-implant reconstruction.\n* Small- to medium-sized breasts with ptosis grade 2 or less.\n* Written informed consent provided.\n\nExclusion Criteria:\n\n* Preoperative evidence of skin involvement, nipple-areola complex involvement, lymph-node metastases, inflammatory breast cancer, Paget's disease, mesenchymal breast tumors, or recurrent breast cancer.\n* Previous ipsilateral breast surgery.\n* Previous thoracic radiation therapy.\n* Heavy smoking (\\>20 cigarettes\u002Fday), uncontrolled diabetes mellitus, or body mass index \\>30.\n* ASA score 3 or higher.\n* Ongoing pregnancy","FEMALE",{"count":61,"type":21},10,[24],"This single-center prospective study will evaluate the feasibility and safety of endoscopic nipple-sparing mastectomy (E-NSM) performed through a single axillary incision in selected women with breast cancer undergoing direct-to-implant breast reconstruction. The study will assess procedural feasibility, completeness of resection, short-term postoperative complications, and patient-reported outcomes",[65,66],"Breast Cancer - Ductal Carcinoma in Situ (DCIS)","Breast Cancer",[68,69,70,71],"Breast","Endoscopic Nipple-Sparing","Mastectomy","E-NSM","2026-03-30",{"date":74,"type":42},"2026-04-02",{"date":76,"type":42},"2025-06-11",{"date":78,"type":21},"2026-12-30",{"name":48,"class":49},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":105,"locationsCount":106},"100630915","enhanced-recovery-after-surgery-eras-in-patients-with-peritoneal-carcinomatosis-undergoing-cytoreductive-surgery-with-or-without-hyperthermic-intraperitoneal-chemotherapy-hipec-100630915","NCT07493876","Enhanced Recovery After Surgery (ERAS) in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)","Prospective Multicenter Interventional Pre-Post Study of an Enhanced Recovery After Surgery (ERAS) Protocol in the Perioperative Management of Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery With or Without HIPEC (EPICH)","EPICH","Inclusion Criteria:\n\n* Written informed consent signed before the procedure\n* Histological or cytological diagnosis of advanced solid tumor with documented peritoneal carcinomatosis originating from one of the following: peritoneal mesothelioma or other primary malignant peritoneal tumor, gynecologic tumor, gastric tumor, or intestinal tumor\n* Age \\>18 years\n* ECOG performance status ≤1\n* ASA score ≤3\n\nExclusion Criteria:\n\n* Missing written informed consent\n* ASA score ≥4\n* Palliative surgery or other unplanned surgery\n* Severe renal insufficiency, severe hepatic insufficiency, severe heart failure, recent myocardial infarction, or severe arrhythmia\n* Immunocompromised patients, patients receiving immunosuppressive therapy, or patients with immune system diseases",{"count":89,"type":21},300,[24],"This prospective multicenter interventional pre-post study aims to evaluate the effect of implementing an Enhanced Recovery After Surgery (ERAS) protocol in patients with peritoneal carcinomatosis undergoing cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC). Approximately 300 patients will be enrolled across 20 Italian centers. During an initial pre-intervention period, usual perioperative management will be described; during a subsequent intervention period, participating centers will apply a predefined ERAS protocol. The primary objective is to assess the effect of ERAS implementation on mean postoperative hospital length of stay.",[93],"Peritoneal Carcinomatosis",[95,96,97,98,99],"Cytoreductive Surgery","HIPEC","Enhanced Recovery After Surgery","ERAS","Peritoneal Surface Malignancies",{"date":101,"type":42},"2026-04-03",{"date":103,"type":42},"2025-01-23",{"date":46,"type":21},{"name":48,"class":49},2,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":131,"locationsCount":50},"100632263","galenos-1-in-head-and-neck-lung-and-rectal-cancer-patients-100632263","NCT07511413","GALENOS 1 in Head and Neck, Lung, and Rectal Cancer Patients","An Observational Study on Longitudinal Nutritional Status and Body Composition Changes in Head and Neck Cancer, Lung Cancer and Rectal Cancer Patients During Antineoplastic Treatments","GALENOS 1","Inclusion Criteria:\n\n* Written informed consent provided before study procedures\n* Male or female participants aged 18 years or older\n* Histological or cytological documentation of head and neck squamous cell carcinoma, locally advanced rectal cancer, or lung cancer\n* Candidate for standard antineoplastic treatment according to clinical practice\n* ECOG Performance Status score less than 2\n* Adequate kidney, liver, and bone marrow function\n* Ability to adhere to study visits and protocol requirements\n\nExclusion Criteria:\n\n* Incomplete recovery from surgery before start of antineoplastic treatment\n* Other additional malignancies progressing or requiring active treatment within the previous 3 years, except localized basal cell carcinoma, localized squamous cell carcinoma of the skin, or cervical carcinoma in situ\n* Active infection requiring systemic antibiotic therapy Serious or unstable medical conditions, psychiatric disorders, or substance abuse that would interfere with study compliance\n* Receipt of any live vaccine within 30 days before planned start of study therapy\n* Active cardiac pacing\u002Fpacing implants\u002Fneurostimulators\u002Fhearing systems not compatible with bioimpedance analysis\n* Edema and\u002For ascites interfering with body weight evaluation or bioimpedance analysis\n* Enteral or parenteral nutritional support at baseline",{"count":116,"type":21},110,"OBSERVATIONAL","GALENOS 1 is a prospective observational study designed to explore longitudinal changes in nutritional status and body composition in patients with head and neck squamous cell carcinoma, locally advanced rectal cancer, and lung cancer undergoing standard antineoplastic treatments. The study is the preparatory observational component of the FOR-GALE PREVENTION project, which aims to support the future development of a galenic immunonutrition dietary supplement intended to reduce adverse events and improve treatment compliance",[27,28,29],[27,29,28,35,34,121,122,123,124,36,37,32,125,31,33],"Skeletal Muscle Mass","Sarcopenia","Bioimpedance Analysis","Handgrip Strength","Treatment Tolerance",{"date":127,"type":42},"2026-04-06",{"date":129,"type":42},"2024-09-23",{"date":46,"type":21},{"name":48,"class":49},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":149,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":50},"100630940","mimicc-study-in-patients-with-colorectal-cancer-100630940","NCT07494201","MIMICC Study in Patients With Colorectal Cancer","Analysis of MicroRNA Expression and Microbiome Composition During the Diagnostic-Therapeutic Pathway of Patients With Colorectal Carcinoma","MIMICC","Inclusion Criteria:\n\n* Histologically confirmed colon or rectal cancer on endoscopic biopsy\n* Any T stage, any N stage, M0-M1, candidate for surgical intervention\n* Colon tumors with indication for surgical resection with curative intent, including right hemicolectomy, left hemicolectomy, transverse colon resection, colectomy, or total proctocolectomy\n* Rectal tumors with indication for upfront surgery or neoadjuvant chemoradiotherapy\n* Written informed consent signed before any study procedure\n* Age between 18 and 75 years\n\nExclusion Criteria:\n\n* Tis\u002FT1 lesions or lesions almost completely resected by endoscopic polypectomy\u002FEMR\u002FESD\n* Use of immunosuppressive or immunomodulatory drugs within the previous 6 months\n* Current or previous diagnosis of other solid or hematologic malignancies\n* Inability or refusal to provide informed consent\n* Inability or refusal to be followed at the study institution\u002Fnetwork","75 Years",{"count":142,"type":21},2500,[24],"This multicenter prospective interventional study will evaluate stool and saliva microRNA expression and microbiome composition in patients with histologically confirmed colon or rectal cancer during key phases of the diagnostic and therapeutic pathway. The study aims to confirm and refine molecular signatures associated with colorectal cancer, assess the diagnostic and prognostic potential of salivary biomarkers, and characterize dynamic molecular changes during treatment and follow-up",[146,147,148],"Colorectal Cancer","Colon Cancer","Rectal Cancers",[150,151,152,153,154,155,156,157],"microRNA","microbiome","stool biomarkers","saliva biomarkers","colorectal cancer","anastomotic leak","diet","recurrence","2026-03-20",{"date":160,"type":42},"2026-03-27",{"date":162,"type":42},"2025-09-15",{"date":164,"type":21},"2028-06-30",{"name":48,"class":49},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":176,"conditions":177,"keywords":180,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":50},"100629778","low-glucosehigh-fat-intake-dietary-regimen-as-a-tool-for-empowering-diagnostic-accuracy-of-2-18ffdg-petct-in-lepidic-predominant-growth-lung-adenocarcinoma-100629778","NCT07479095","Low-glucose\u002FHigh-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET\u002FCT in Lepidic-predominant Growth Lung Adenocarcinoma","KETO-FDG Lung","Inclusion Criteria:\n\n* Written informed consent.\n* Age 18 years or older.\n* CT evidence of a lung nodule suspicious for LPA or lung biopsy positive for LPA.\n* Target nodule diameter at least 10 mm.\n* ECOG performance status 0 to 2.\n* Willingness and ability to adhere to a controlled ketogenic diet for 7 days.\n* Ability to comply with study procedures and visit schedule.\n\nExclusion Criteria:\n\n* Not suitable for prolonged imaging procedures.\n* Renal failure.\n* Type 1 diabetes mellitus.\n* Pancreatitis.\n* Severe dyslipidemia.\n* Other malignancies that are progressing or required active treatment within the previous 3 years.\n* Serious or unstable medical, psychiatric, or substance use disorders that could interfere with study participation.\n* Pregnancy or breastfeeding.\n* Refusal to participate",{"count":174,"type":21},30,[24],"This study evaluates whether a 7-day ketogenic dietary regimen before 2-\\[18F\\]FDG PET\u002FCT can improve the diagnostic accuracy of imaging in adults with suspected or histologically confirmed lepidic-predominant lung adenocarcinoma (LPA). LPA frequently shows low glucose metabolism and may yield false-negative FDG PET\u002FCT results. Approximately 30 participants will undergo a tailored ketogenic diet for 7 days before PET\u002FCT. Imaging results will be compared with histopathology and additionally assessed against literature-reported diagnostic performance and a matched retrospective institutional cohort.",[178,179],"Lepidic-Predominant Lung Adenocarcinoma","Lung Adenocarcinoma",[181,182,183,184,185],"2-[18F]FDG PET\u002FCT","Ketogenic Diet","Lepidic Adenocarcinoma","Lung Nodule","Diagnostic Accuracy","2026-03-18",{"date":158,"type":42},{"date":189,"type":42},"2025-07-03",{"date":191,"type":21},"2027-03-30",{"name":48,"class":49},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":22,"phases":204,"briefSummary":205,"conditions":206,"keywords":210,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":224},"100629792","progel-platinum-for-air-leak-reduction-after-vats-lobectomy-for-nsclc-100629792","NCT07479277","Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC","A Multicenter, Randomized, Parallel-Group Trial Evaluating Progel Platinum Added to Mechanical Stapling Versus Mechanical Stapling Alone in Patients Undergoing VATS Upper or Lower Lobectomy for Non-Small Cell Lung Cancer","E-SEAL","Inclusion Criteria:\n\n* Age ≥18 years\n* Written informed consent\n* Planned VATS upper or lower lobectomy for NSCLC\n* Minimally invasive thoracoscopic approach\n* Middle lobectomy excluded\n\nExclusion Criteria:\n\n* Induction radiochemotherapy or chemo-immunotherapy\n* Severe COPD: GOLD 3 or higher\n* Sleeve resection or extended resection involving other lobes\u002Fchest wall\u002Fpericardium, etc.\n* Albumin intolerance\u002Fallergy\n* Renal insufficiency\n* Redo surgery\n* Use of sealants\u002Fadhesives other than the study approach\n* Expected extensive pleural adhesions","99 Years",{"count":203,"type":21},160,[24],"This multicenter randomized trial evaluates whether routine use of Progel Platinum surgical sealant on stapled fissure lines during VATS upper or lower lobectomy for NSCLC reduces pleural drainage duration compared with standard stapling alone. Secondary objectives include postoperative length of stay, incidence and duration of postoperative air leaks, residual pleural space, safety outcomes, and hospitalization costs.",[207,208,209],"Non-Small Cell Lung Cancer","Postoperative Air Leak","NSCLC",[207,209,211,212,213,214,215,216],"VATS Lobectomy","Postoperative air leak","Pleural drainage","Progel Platinum","Surgical sealant","Thoracic surgery","2026-03-16",{"date":186,"type":42},{"date":220,"type":42},"2026-02-27",{"date":222,"type":21},"2027-12-31",{"name":48,"class":49},6,{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":247,"locationsCount":50},"100629058","a-study-of-biological-genetic-and-constitutional-factors-and-non-invasive-monitoring-to-assess-personal-cancer-risks-100629058","NCT07469709","A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks","A Platform for Assessing Personal Risk of Developing or Recurring of Cancer: Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring of Subclinical Recurrences With Therapeutic Impact","PRO-ACTIVE","Inclusion Criteria:\n\n* Age \\>18 years;\n* Patients with breast cancer, including patients who meet the AIOM criteria for eligibility for BRCA testing and patients with lobular breast cancer;\n* Patients with radically resected colon cancer, including patients with stage III colon cancer and vascular invasion;\n* Patients with ovarian carcinomas;\n* Patients with metastatic melanoma;\n* Patients with stage IIB and IIIA non-small cell lung cancer.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years;\n* Unwillingness or inability to give informed consent",{"count":234,"type":21},850,"The PRO-ACTIVE study aims to develop a clinical-translational program in the field of cancer prevention in all its phases (primary, secondary, and tertiary) to intervene before the clinical and radiological manifestation of the disease. It starts with risk prediction and leads to early diagnosis of the disease or recurrence in the subclinical phase.\n\nThe PRO-ACTIVE study includes the following activities:\n\n* WP1: Integrated DNA-RNA approach for the identification of hereditary markers of predisposition to tumors\n* WP2: Global biological and molecular analysis of the host and tumor for the prevention and monitoring of recurrences\n* WP3: Analysis of the immunological status for the diagnosis of primary prevention and relapses in correlation to genetic and environmental factors\n* WP4: Study of the tumor microenvironment for recurrence prediction",[66,237,238,239,240],"Colo-rectal Cancer","Ovarian Cancer","Melanoma (Skin Cancer)","Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)","2026-03-09",{"date":243,"type":42},"2026-03-13",{"date":245,"type":42},"2024-02-01",{"date":222,"type":21},{"name":48,"class":49},{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":256,"minAge":18,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":50},"100627780","a-prospective-study-to-evaluate-mirna371-and-outcomes-in-patients-with-newly-diagnosed-germ-cell-tumors-100627780","NCT07453082","A Prospective Study to Evaluate miRNA371 and Outcomes in Patients With Newly Diagnosed Germ Cell Tumors","A Prospective Observational Cohort Study to Evaluate miRNA371 and Outcomes in Patients With Newly Diagnosed Germ Cell Tumor","BRIDGE","Inclusion Criteria:\n\n* Patients must be ≥ 18 years of age.\n* Patients must have a new diagnosis of a germ cell tumor confirmed pathologically or serologically (diagnostic elevation of HCG\u002FAFP). All primary sites, stages, histological subtypes of germ cell tumor are eligible. Metachronous second primary germ cell tumors are eligible.\n* If surgery is planned, male patients with Clinical Stage I testicular cancer must have orchiectomy completed within 42 days prior to registration.\n* Patients must have risk of relapse assessment determined by the local investigator prior to registration.\n* Patients must have initial imaging, laboratory and other clinical evaluations (see below) performed within 42 days prior to registration. Imaging reports, pathology reports and performance status will be collected.\n* Patients must have beta-human chorionic gonadotropin (beta-HCG), alpha- fetoprotein (AFP), and lactate dehydrogenase (LDH) assessments within 42 days prior to registration.\n* Patients must agree to provide informed consent and required blood specimens for the duration of the study.\n\nExclusion Criteria:\n\n* Patients with high risk of relapse or metastatic disease.\n* Patients with tumour assessments beyond the time frame required by the protocol.\n* Patients not complaint with the protocol schedule.","MALE",{"count":258,"type":21},100,"This is a observational study aimed at evaluating miRNA 371a-3p (miRNA 371) as a specific marker for presence or absence of clinically detectable viable germ cell malignancy.",[261],"Testicular Germ Cell Tumor","2026-03-03",{"date":264,"type":42},"2026-03-05",{"date":266,"type":42},"2021-07-01",{"date":268,"type":21},"2026-12-31",{"name":48,"class":49},{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":281,"conditions":282,"keywords":285,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":289,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":50},"100589260","a-global-integrated-personalized-stage-related-multimodal-therapeutic-approach-for-rectal-adenocarcinoma-based-on-organ-sparing-and-mininvasivity-100589260","NCT06952101","A Global, Integrated, Personalized, Stage-related, Multimodal Therapeutic Approach for Rectal Adenocarcinoma Based on Organ Sparing and Mininvasivity","INTERPRETE: a Global, Integrated, Personalized, Stage-related, Multimodal Therapeutic Approach for Rectal Adenocarcinoma Based on Organ Sparing and Mininvasivity","INTERPRETE","Inclusion Criteria:\n\n* Patients aged ≥18 yrs old\n* Patients able to sign the informed consent\n* Patients with High Risk pT1 rectal adenocarcinoma endoscopically excised\n* Patients with cT2-3aN0 rectal adenocarcinoma who has complete\u002Fmajor response to EXPERIMENTAL CRT\n* Patients with cT3b4N0-1 rectal adenocarcinoma who has complete\u002Fmajor response to STANDARD CRT\n\nExclusion Criteria:\n\n* cT2-4 any NM0 who don't reach cCR or cMR after experimental\u002Fstandard CRT\n* Pregnancy",{"count":279,"type":21},200,[24],"A phase II, single-center, non-profit, interventional study on patients affected by rectal adenocarcinoma. Patients will be stratified into three groups based on pre-treatment clinical stage. The study investigates and may propose a comprehensive, stage-specific, multimodal approach to rectal adenocarcinoma, with a focus on organ preservation even in early stages (cT1-2N0). When organ-sparing strategies are not feasible, the approach prioritizes minimally invasive techniques (laparoscopic and robotic) to reduce the physical, psychological, and quality-of-life impact on patients.",[283,284],"Rectal Adenocarcinoma","Non Metastatic",[283,286,287,288],"mininvasivity","organ sparing","surgical rectal resection",{"date":264,"type":42},{"date":291,"type":42},"2024-04-30",{"date":293,"type":21},"2030-12-31",{"name":48,"class":49},{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":305,"conditions":306,"keywords":308,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":50},"100595418","prospective-study-on-the-use-of-the-da-vinci-sp-system-in-urological-surgery-100595418","NCT07032194","Prospective Study on the Use of the Da Vinci SP System in Urological Surgery","Use of the Da Vinci Single Port Robotic System in Urological Surgery: A Prospective Observational Study (SP-URO)","SP-URO","Inclusion Criteria:\n\n* Signed informed consent and data privacy consent\n* Clinical indication for urologic robotic surgery per EAU guidelines or clinical trial eligibility\n* ECOG Performance Status 0-1\n* Life expectancy ≥ 10 years\n* Availability of preoperative clinical data\n* Willingness to comply with follow-up visits and data collection\n* Eligibility for robotic surgery\n\nExclusion Criteria:\n\n* Unsuitability for anesthesia\n* Cognitive or psychiatric disorders affecting consent or compliance",{"count":304,"type":21},250,"A prospective observational study aimed at evaluating the feasibility, safety, and effectiveness of the Da Vinci SP robotic system for urologic procedures at IRCCS Candiolo. The study collects perioperative, oncologic, and functional outcomes, with exploratory comparisons to the multiport Da Vinci Xi system.",[307],"Urologic Surgical Procedure",[309,310,311],"Da Vinci Single Port (SP) System","Urologic Surgery","multiport","2025-06-13",{"date":314,"type":42},"2025-06-22",{"date":316,"type":42},"2025-02-19",{"date":318,"type":21},"2031-12-31",{"name":48,"class":49},{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":256,"minAge":18,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":330,"conditions":331,"keywords":333,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":345,"locationsCount":106},"100541818","inside-identification-of-genomic-screening-pathways-in-cancer-patients-with-dna-repair-alterations-100541818","NCT06334809","INSIDE: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations","Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations","INSIDE","Inclusion Criteria:\n\n* Age \\> 18 years\n* Diagnosis of prostate cancer as indicated below:\n\nCohort A: patients with high risk localized prostate cancer (defined as \\>cT3 or PSA \\> 20 ng\u002FmL or presence of ECE or SVIat mpMRI), with tissue available from diagnostic biopsy\u002F prostatectomy undergoing or who underwent curative treatment (prostatectomy\u002F radical radiotherapy) but have not started a FU pathway.\n\nCohort B: patients with de novo metastatic hormone sensitive prostate cancer (mHSPC) with tissue available from diagnostic biopsy of the primary and when possiblepossible, from a metastatic site. Patients must either have not started a standard treatment or have started for not longer than 3 months.\n\nCohort C: patients with metastatic castration resistant prostate cancer tissue (mCRPC) progressing on a standard treatment with available from biopsy of a metastatic site, and when possiblepossible, from the primary.\n\n* Ability to understand and consent to informed consent;\n* Patient must be compliant with receiving a biopsy of the metastatic site (cohort C) and with FU assessments schedule\n\nExclusion Criteria:\n\n• Patients not willing to comply with study's procedures or fulfilling the inclusion criteria.",{"count":329,"type":21},400,"400 patients will be enrolled and divided into 3 cohorts: Cohort A: patients with high risk localized prostate cancer (PC) defined as \\>cT3 or PSA \\> 20 ng\u002FmL or presence of ECE or SVI at mpMRI;\n\nCohort B: patients with de novo metastatic hormone sensitive prostate cancer (mHSPC);\n\nCohort C: patients with metastatic castration resistant prostate cancer (mCRPC) progressing on a standard treatment.",[332],"Prostate Cancer",[334,335,336,337,338],"prostate cancer","mHSPC","castration-resistant","PARP inhibitory","mCRPC","2025-06-10",{"date":341,"type":42},"2025-06-12",{"date":343,"type":42},"2023-03-09",{"date":222,"type":21},{"name":48,"class":49},{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":256,"minAge":354,"maxAge":201,"enrollmentInfo":355,"targetDuration":4,"studyType":22,"phases":357,"briefSummary":358,"conditions":359,"keywords":361,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":375,"locationsCount":106},"100540570","artificial-intelligence-3d-augmented-reality-robot-assisted-radical--prostatectomy-vs-no3d-intervention-100540570","NCT06318559","Artificial Intelligence 3D Augmented Reality Robot-Assisted-Radical- Prostatectomy v.s. no3D Intervention","RIDERS: Artificial Intelligence 3D Augmented Reality Robot-Assisted-Radical- Prostatectomy v.s. no3D Intervention: a Prospective Multicenter Randomized Controlled Trial","RIDERS","Inclusion Criteria:\n\n1. Signature of the written informed consent and consent to the use of personal data\n2. Age \\> 40 years and male sex\n3. Pre-operative MRI performed according to ESUR recommendations and reporting in accordance with PiRads V.2\n4. Disease with evidence of bulging or radiological T3 on pre-operative MRI\n5. Histological diagnosis of acinar type prostate cancer in the area highlighted on MRI\n6. Absence of bulky (\\>3 cm), bony or visceral retroperitoneal or pelvic lymph node metastatic lesions\n7. Patients eligible for radical prostatectomy + pelvic lymphadenectomy\n8. ECOG PS 0-1\n9. Life expectancy ≥ 5 years\n10. Patients motivated to preserve erection and with pre-operative sexual activity with IIEF \\>17\n11. Availability of the patient's pre-operative clinical data\n12. Patients must be available to carry out the visits foreseen in the follow-up of the protocol and consent to data collection\n\nExclusion Criteria:\n\n1. Special histotypes of prostate cancer\n2. Patients with PSA \\> 100 ng\u002Fml at diagnosis\n3. Inability to perform MRI (pacemaker wearers, claustrophobia...) or MRI of inadequate quality to obtain the HA3DTM 3D reconstruction\n4. Concomitant treatment with other antineoplastic drugs including investigational endocrine therapies\n5. Serious uncontrolled concomitant medical condition or disease including active, uncontrolled infections\n6. Patients with dementia or psychiatric illness that limit compliance with study requirements or that may prevent understanding and\u002For signing informed consent.","40 Years",{"count":356,"type":21},120,[24],"This is a prospective randomized multicenter study aimed at comparing 3D AI-AR-RARP vs. no 3D, verifying the impact of this new technology on oncological and functional outcomes after the procedure.",[360],"Cancer of Prostate",[362,360,363,364,365,366,367,368],"3D AI-AR-RARP","prostate surgery","Hyper-Accuracy 3D reconstruction (HA3DTM)","Riders","computer vision","Robot-assisted","laparoscopic radical prostatectomy","2024-03-15",{"date":371,"type":42},"2024-03-19",{"date":373,"type":42},"2022-06-29",{"date":222,"type":21},{"name":48,"class":49},{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":382,"eligibilityCriteria":383,"healthyVolunteers":11,"sex":256,"minAge":354,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":22,"phases":386,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":50},"100503244","robotic-hemi-prostatectomy-with-urethral-preservation-in-low-and-intermediate-risk-monolateral-prostate-cancer-100503244","NCT05832736","Robotic Hemi-Prostatectomy With Urethral Preservation in Low and Intermediate Risk Monolateral Prostate Cancer","Robotic Hemi-Prostatectomy With Urethral Preservation in Low and Intermediate Risk Monolateral Prostate Cancer: a Prospective Idea, Development, Exploration, Assessment and Long-term Follow-up (I.D.E.A.L.) Trial","RETURN","Inclusion Criteria:\n\n* Signature of the informed consent and consent to the use of personal data\n* Prostate Specific Antigen (PSA) \\\u003C 20 ng\u002FmL\n* Unilateral organ-confined disease on MRI (performed according to ESUR recommendations and reported according to PiRads V.2) or PET-PSMA (performed according to the recommendations of the EANM and reported according to \"EANM standardized reporting guidelines v1.0 for PSMA-PET\")\n* Histological diagnosis of acinar-type prostate cancer unilateral on target biopsy and\u002For standard biopsy with ISUP \\\u003C 3 and ipsilateral on imaging investigations\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1\n* Life expectancy ≥ 5 years\n* Availability of the patient's pre-operative clinical data\n* Patients must be available to carry out the follow-up visits defined by the protocol\n* Absence of retroperitoneal, lymph nodal, bone or visceral metastatic lesions\n* Patients eligible for robot-assisted radical prostatectomy\n\nExclusion Criteria:\n\n* Special histotypes of prostate cancer\n* Patients with PSA \\> 20 ng\u002Fml at diagnosis\n* Impossibility to perform MRI (with pacemakers, claustrophobia…) or PET-PSMA\n* Previous prostate surgery (TURP, adenomectomy)\n* Concomitant treatment with other antineoplastic drugs including investigational endocrine therapies\n* Serious underlying disease or uncontrolled medical condition including active and uncontrolled infections\n* Patients with dementia or psychiatric illness that limit compliance with study requirements or that could prevent understanding and\u002For signing the informed consent.",{"count":385,"type":21},36,[24],"On the basis of the now consolidated literature and clinical experience of focal therapies, the execution of partial prostatectomy\u002Fhemiprostatectomy with robot-assisted laparoscopic technique can be proposed in a well-selected cohort of patients.\n\nThe hypothesis is that with this technique it is possible to achieve excellent levels of disease control, in terms of positive surgical margins (PSM) and biochemical recurrence of the disease (BCR), against a minimal impact as regards postoperative functional outcomes (continence and sexual power).",[332],"2023-09-22",{"date":391,"type":42},"2023-09-26",{"date":393,"type":42},"2023-04-12",{"date":395,"type":21},"2028-10",{"name":48,"class":49},""]